D²EFT Graphical Informed Consent
D²EFT-GIC
Acceptability and Feasibility of a Graphical Informed Consent in the Informed Consent Process of D²EFT Study
1 other identifier
observational
12
1 country
1
Brief Summary
D²EFT-GIC is a substudy of D²EFT study (NCT03017872), a randomised clinical trial of second-line antiretroviral therapies. The goal of D²EFT-GIC is to evaluate a novel tool, the "Graphical Informed Consent" (GIC), within D²EFT. The GIC is designed to supplement the informed consent process with a set of culturally- and gender-adapted illustrations, with an explanatory script for researchers, that complements the mandatory written participant information sheet and consent form. The investigators propose to assess the acceptability and feasibility of this tool from the participants and researchers perspectives. The GIC will be first pre-tested in one or more site(s) - where the informed consent process is challenging because of literacy, language or culture barriers - in 10 prospective participants for D²EFT. If this stage shows there is no negative impact of the GIC on the consent process, the second stage will study the feasibility of implementing the GIC in the usual practice.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
Started Mar 2021
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
December 3, 2020
CompletedFirst Posted
Study publicly available on registry
December 16, 2020
CompletedStudy Start
First participant enrolled
March 22, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
December 31, 2021
CompletedJanuary 11, 2022
January 1, 2022
9 months
December 3, 2020
January 6, 2022
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Proportion of prospective D²EFT participants to whom researchers offered the supplemental GIC during the informed consent process (Stage 2)
Utilisation (uptake) of the GIC by researchers: number of times researchers offered the supplemental GIC during the informed consent process of D²EFT divided by the total number of prospective participants who underwent informed consent for D²EFT during the substudy period when the GIC is freely available
Up to 1 year
Secondary Outcomes (3)
Proportion of participants who find the illustrations helpful (Stage 1)
Up to 3 months
Proportion of researchers who think there are issues in using the GIC (Stage 1)
Up to 3 months
Proportion of participants who accept to undergo the D²EFT informed consent process with GIC (Stage 2)
Up to 1 year
Study Arms (2)
Prospective participants in D²EFT study
HIV-positive persons who are eligible for the D²EFT study will be proposed to receive the research-related information with the set of pictures (GIC)
Researchers obtaining informed consent for D²EFT study
Healthcare givers involved in the participant informed consent process of D²EFT
Interventions
The GIC (set of illustrations that complement the written information and consent form) will be proposed to prospective participants by researchers, systematically during the pre-test (stage 1). If the stage 1 shows no negative impact of the GIC on the consent process, the stage 2 will be implemented and the GIC will be proposed by researchers when they feel it could be beneficial for the participant.
Eligibility Criteria
Prospective participants for D²EFT study and researchers obtening the informed consent process.
You may qualify if:
- Fulfil the eligibility criteria for D²EFT and willing to undertake D²EFT informed consent process;
- Being able to give a verbal consent for the D²EFT-GIC.
You may not qualify if:
- Unwilling to comply with the substudy requirements.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Kirby Institutelead
- Institute of Human Virology, Nigeriacollaborator
Study Sites (1)
Institute of Human Virology Nigeria (IHVN)
Abuja, Nigeria
Study Officials
- PRINCIPAL INVESTIGATOR
Mark Polizzotto, MD, PhD
The Kirby Institute, UNSW
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- OTHER GOV
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
December 3, 2020
First Posted
December 16, 2020
Study Start
March 22, 2021
Primary Completion
December 31, 2021
Study Completion
December 31, 2021
Last Updated
January 11, 2022
Record last verified: 2022-01